Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Acute promyelocytic leukemia


Other Names for this Disease
  • Acute myeloblastic leukemia type 3
  • Acute myeloid leukemia with t(15;17)(q22;q12);(PML/RARalpha) and variants
  • AML M3
  • AML with t(15;17)(q22;q12);(PML/RARalpha) and variants
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

News & Events


NCATS Co-Sponsored Conferences

  • Advancing Symptom Clusters Research on Rare Cancers, Wednesday, June 17, 2015
    Location: NIH Neuroscience Building, Bethesda, MD
    Description: <p>It is intended that the in-depth, interdisciplinary dialogue of this expert working group will formulate an emerging consensus on a working definition of symptom clusters and, specific gaps and opportunities that provide a foundation for a transformative strategic blueprint to guide future symptom cluster research in rare cancers. In addition, it is anticipated that workshop proceedings will inform a funding opportunity announcement.</p>

  • The Jak/Stat Pathway: 20 Years from Discovery to Drugs, Thursday, September 22, 2011 - Saturday, September 24, 2011
    Location: NIH Natcher Center, Bethesda, MD
    Description: As a scientific conference, the primary goal is the dissemination of recent data and developments in the field to intersted researchers in the field. The conference includes a scientific program and reception, which will help to foster collaboration and networking. Participants should achieve a better understanding of the state of the art research in this exciting and clinically relevant field.

  • Overcoming Barriers to International Clinical Trials for Rare Cancers , Friday, December 10, 2010
    Location: Bethesda, Maryland
    Description: The goals of this conference were to introduce key institutional players to the topic of international clinical trials in rare cancers and to establish an ongoing dialogue. Participants left the meeting with a set of specific priorities that need to be enacted to promote these trials. The meeting promoted consensus on the way that resources are prioritized to address rare cancers. Participants were asked to convey the content of the meeting to their constituencies and to follow up with pilot concepts.

Other Names for this Disease
  • Acute myeloblastic leukemia type 3
  • Acute myeloid leukemia with t(15;17)(q22;q12);(PML/RARalpha) and variants
  • AML M3
  • AML with t(15;17)(q22;q12);(PML/RARalpha) and variants
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.